biobucks

Graphic image of a pen signing a signature while two strangelooking business people cheer

Ipsen taps Biomunex's MAITs to treat solid tumors in $610M bet

The biobuck bet has landed the French drugmaker exclusive global rights to a preclinical Biomunex prospect that engages a subset of cytotoxic T cells.

Nick Paul Taylor Dec 3, 2024 6:00am

Brain and money connected by a thread on a white background

Acadia inks $582M biobucks pact for Danish biotech's neuro asset

Nov 26, 2024 5:00pm

GSK pays Flagship biotech $80M for preclinical neuro pact

Nov 12, 2024 6:30am

AbbVie pays $65M for options on EvolveImmune's T-cell engagers

Oct 31, 2024 10:00am

Biogen buys in to molecular glues with deal worth up to $1.45B

Oct 30, 2024 10:50am

Novartis inks $150M deal for autoimmune molecular glue

Oct 28, 2024 7:00am